Agios Pharmaceuticals Added to NASDAQ Biotechnology Index
The NASDAQ Biotechnology Index, launched in 1993, includes securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as biotechnology or pharmaceutical companies. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology and ranked on semi-annual basis.
The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ
Biotechnology Index(SM) Fund. All securities in the NASDAQ Biotechnology
Index are listed on the
Agios Pharmaceuticals is focused on discovering and developing novel drugs to treat cancer and inborn errors of metabolism, or IEMs, which are rare genetic metabolic diseases, through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class lead product candidates in cancer metabolism and IEMs in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics. For more information, please visit our website at www.agios.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those regarding Agios’ expectations
and beliefs about its plans and strategies. The words “anticipate,”
“believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,”
“project,” “would” and similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements
contain these identifying words. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual events
or results to differ materially from Agios’ current expectations and
beliefs, including risks and uncertainties relating to: Agios’ ability
to successfully commence and complete necessary preclinical and clinical
development of its product candidates; Agios’ results of clinical trials
and preclinical studies, including subsequent analysis of existing data
and new data received from ongoing and future studies; Agios’ ability to
maintain its collaboration with third parties on acceptable terms; the
content and timing of decisions made by the U.S.